Skip to main content
SpringerLink
Log in

Value of MIBG in the Differential Diagnosis of Neurodegenerative Disorders

  • Chapter
  • First Online:
Book cover PET and SPECT in Neurology

Abstract

123I-metaiodobenzylguanidine (MIBG) has a history of over 20 years as a marker of myocardial sympathetic activity and has been used for assessment of various cardiac diseases. Reduced cardiac MIBG uptake in myocardial scintigraphy has been reported in patients with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), rapid eye movement sleep behavior disorder (RBD), and familial PD linked to SNCA duplication. In 2005, the Dementia with Lewy Bodies Consortium considered 123I-MIBG myocardial scintigraphy a “supportive” diagnostic tool. Recently, reliable and clear evidence for the usefulness of 123I-MIBG scintigraphy in the diagnosis of Lewy body disorders has been accumulated, and it has become increasingly popular, whereas reduction of cardiac MIBG accumulation was reported in some cases of atypical parkinsonian syndromes such as progressive supranuclear palsy and multiple system atrophy. In 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropan (FP-CIT) SPECT-supplemented MIBG scintigraphy of PD and DLB, FP-CIT binding in basal ganglia is closely related to cardiac MIBG uptake. Reduced 123I-MIBG cardiac uptake might be a “suggestive” feature for Lewy body diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

123I-IMP:

N-isopropyl-p-[123I]-iodoamphetamine

AD:

Alzheimer’s-type dementia

CBD:

Corticobasal degeneration

DLB:

Dementia with Lewy bodies

DOPS:

Dihydroxyphenylserine

ECD:

Ethyl cysteinate dimer

FDG:

Fluorodeoxyglucose

FP-CIT:

N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropan

HMPAO:

Hexamethyl-propylene-amine-oxine

LBD:

Lewy body disease

MAO:

Monoamine oxidase

MIBG:

Metaiodobenzylguanidine

PAF:

Pure autonomic failure

PD:

Parkinson’s disease

PSP:

Progressive supranuclear palsy

References

  • Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of Parkinsonian syndromes. Clin Auton Res 11:351–355

    Article  CAS  PubMed  Google Scholar 

  • Braune S, Reinhardt M, Bathmann J et al (1998) Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson’s disease with autonomic failure. Acta Neurol Scand 97:307–314

    Article  CAS  PubMed  Google Scholar 

  • Braune S, Reinhardt M, Schnitzer R et al (1999) Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53:1020–1025

    Article  CAS  PubMed  Google Scholar 

  • Druschky A, Hilz MJ, Platsch G et al (2000) Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG- SPECT. J Neurol Sci 175:3–12

    Article  CAS  PubMed  Google Scholar 

  • Glowniak JV, Turner FE, Gray LL et al (1989) Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 30:1182–1191

    CAS  PubMed  Google Scholar 

  • Goldstein DS, Holmes C, Li ST, Bruce S et al (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338–347

    Article  CAS  PubMed  Google Scholar 

  • Hakusui S, Yasuda T, Yanagi T et al (1994) A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84

    Article  CAS  PubMed  Google Scholar 

  • Hanyu H, Shimizu S, Hirao K et al (2006) Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 33:248–253

    Article  PubMed  Google Scholar 

  • Hirayama M, Hakusui S, Koike Y et al (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230–234

    Article  CAS  PubMed  Google Scholar 

  • Iwanaga K, Wakabayashi K, Yoshimoto M et al (1999) Lewy body type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 52:1269–1271

    Article  CAS  PubMed  Google Scholar 

  • Iwasa K, Nakajima K, Yoshikawa H (1998) Decreased myocardial 123I-MIBG uptake in Parkinson’s disease. Acta Neurol Scand 97:303–306

    Article  CAS  PubMed  Google Scholar 

  • Kajimoto Y, Miwa H, Okawa-Izawa M et al (2009) Transcranial sonography of the substantia nigra and MIBG myocardial scintigraphy: complementary role in the diagnosis of Parkinson’s disease. Parkinsonism Relat Disord 15:270–272

    Article  PubMed  Google Scholar 

  • Kashihara K, Ohno M, Kawada S et al (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101

    CAS  PubMed  Google Scholar 

  • Kollensperger M, Seppi K, Liener C et al (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771–1776

    Article  PubMed  Google Scholar 

  • Lee PH, Yeo SH, Yong SW et al (2007) Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry 78:1250–1252

    Article  PubMed Central  PubMed  Google Scholar 

  • Lobotesis K, Fenwick JD, Phipps A et al (2001) Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56:643–649

    Article  CAS  PubMed  Google Scholar 

  • McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872

    Article  CAS  PubMed  Google Scholar 

  • McKeith I, O’Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6:305–313

    Article  PubMed  Google Scholar 

  • Merlet P, Valette H, Dubois-Rande JL et al (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477

    CAS  PubMed  Google Scholar 

  • Mitsui J, Saito Y, Momose T et al (2006) Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson’s disease. J Neurol Sci 243:101–104

    Article  CAS  PubMed  Google Scholar 

  • Miyamoto T, Miyamoto M, Inoue Y et al (2006) Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67:2236–2238

    Article  CAS  PubMed  Google Scholar 

  • Mori H, Oda M, Komori T et al (2002) Lewy bodies in progressive supranuclear palsy. Acta Neuropathol 104:273–278

    CAS  PubMed  Google Scholar 

  • Mori K, Iwasaki Y, Ito M et al (2012) Decreased myocardial uptake of meta-iodobenzylguanidine in an autopsy-confirmed case of corticobasal degeneration with Lewy bodies restricted to the sympathetic ganglia. Clin Neurol 52:405–410

    Google Scholar 

  • Movellino F, Bagnato A, Salsone M et al (2010) Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging 31:1903–1933

    Article  Google Scholar 

  • Nagayama H, Hirayama M et al (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nakajima K, Bunko H, Taki J et al (1990) Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 119:1329–1337

    Article  CAS  PubMed  Google Scholar 

  • Nakajima K, Yoshita M, Matsuo S et al (2008) Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Mol Imaging 52:378–387

    CAS  Google Scholar 

  • Nakajima K, Okuda K, Matsuo S et al (2012) Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging 39:113–119

    Article  CAS  PubMed  Google Scholar 

  • Oka H, Toyoda C, Yogo M et al (2011) Reduced cardiac 123I-MIBG uptake reflects sympathetic dysfunction in de novo Parkinson’s disease. J Neural Transm 118:1323–1327

    Article  PubMed  Google Scholar 

  • Orimo S, Ozawa E, Nakade S et al (1999) 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Orimo S, Ozawa E, Nakade S et al (2003) [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson’s disease. Intern Med 42:127–128

    Article  PubMed  Google Scholar 

  • Orimo S, Amino T, Yokouchi M et al (2005) Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20:1350–1353

    Article  PubMed  Google Scholar 

  • Orimo S, Kanazawa T, Nakamura A et al (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81–86

    Article  PubMed  Google Scholar 

  • Orimo S, Suzuki M, Inaba A et al (2012) 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative Parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 18:494–500

    Article  PubMed  Google Scholar 

  • Quattrone A, Bangnato A, Annesi G et al (2008) Myocardial 123I-metaiodobenzylguanidine uptake in genetic Parkinson’s disease. Mov Disord 23:21–27

    Article  PubMed  Google Scholar 

  • Rascol O, Schelosky L (2009) 123I-metaiodobezylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord 24(Suppl 2):S732–S741

    Article  PubMed  Google Scholar 

  • Reinhardt MJ, Jungling FD, Krause TM et al (2000) Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595–600

    Article  CAS  PubMed  Google Scholar 

  • Saiki S, Hirose G, Sakai K et al (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220:105–111

    Article  PubMed  Google Scholar 

  • Solanki KK, Bomanji J, Moyes J et al (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521

    Article  CAS  PubMed  Google Scholar 

  • Spiegel J, Hellwig D, Farmakis G et al (2007) Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov Disord 22:1004–1008

    Article  PubMed  Google Scholar 

  • Suchowersky O, Reich S, Perlmutter J et al (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975

    Article  CAS  PubMed  Google Scholar 

  • Südmeyer M, Antke C, Zizek T et al (2011) Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative Parkinsonism: a multidimensional statistical approach. J Nucl Med 52:733–740

    Article  PubMed  Google Scholar 

  • Takatsu H, Nagashima K, Murase M et al (2000a) Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 284:44–45

    Article  CAS  PubMed  Google Scholar 

  • Takatsu H, Nishida H, Matsuo H et al (2000b) Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radio-labeled MIBG. J Nucl Med 41:71–77

    CAS  PubMed  Google Scholar 

  • Taki J, Nakajima K, Hwang EH et al (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573

    Article  CAS  PubMed  Google Scholar 

  • Taki J, Yoshita M, Yamada M et al (2004) Significance of 123IMIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 18:453–461

    Article  PubMed  Google Scholar 

  • Tijero B, Gomez-Esteban JC, Llorens V et al (2010) Cardiac sympathetic denervation precedes nigrostrial loss in the E46K mutation of the alpha-synuclein gene (SNCA). Clin Auton Res 20:267–269

    Article  CAS  PubMed  Google Scholar 

  • Treglia G, Gason E (2012) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 22:111–117

    Article  PubMed  Google Scholar 

  • Treglia G, Stefanelli A, Gason E et al (2011) Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 113:823–829

    Article  PubMed  Google Scholar 

  • Treglia G, Cason E, Stefanelli A et al (2012) MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 22:43–55

    Article  PubMed  Google Scholar 

  • Valldeoriola F, Gaig C, Muxi A et al (2011) 123I-MIBG cardiac uptake and smell identification in Parkinsonian patients with LRRK2 mutations. J Neurol 258:1126–1132

    Article  PubMed Central  PubMed  Google Scholar 

  • Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38(Suppl 2):2–7

    Article  PubMed  Google Scholar 

  • Watanabe H, Ieda T, Katayama T et al (2001) Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatr 70:781–783

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yoshida M, Fukumoto Y, Kuroda Y et al (1997) Sympathetic denervation of myocardium demonstrated by 123I-MIBG scintigraphy in pure autonomic failure. Eur Neurol 38:291–296

    Article  CAS  PubMed  Google Scholar 

  • Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67

    Article  CAS  PubMed  Google Scholar 

  • Yoshita M (2000) Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy. Neurology 54:1877–1878

    Article  CAS  PubMed  Google Scholar 

  • Yoshita M, Yamada M (2003) Occipital cerebral hypoperfusion and cardiac sympathetic dysfunction in dementia with Lewy bodies and MIBG scintigraphy in patients with dementia of the Alzheimer’s type. Neurology 60(Suppl 1):A208

    Google Scholar 

  • Yoshita M, Matsubara S, Tada A (1996) Decreased accumulation of 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. Neurol Med 45:221–225

    Google Scholar 

  • Yoshita M, Hayashi M, Hirai S (1998) Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl Med Commun 19:137–142

    Article  CAS  PubMed  Google Scholar 

  • Yoshita M, Taki J, Yamada M. (2001) A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 71:583–588

    Google Scholar 

  • Yoshita M, Taki J, Yokoyama K et al (2006) Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850–1854

    Article  CAS  PubMed  Google Scholar 

  • Yoshita M, Noto D, Takahashi K et al (2008) 123I-MIBG scintigraphy in PSP, CBD and IPD. Clin Auton Res 18:281

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Institute for Clinical Research, Dementia Medical Center, Hokuriku National Hospital, National Hospital Organization, 5963 Nobusue, Nanto, Toyama, 939-1893, Japan

    Mitsuhiro Yoshita MD, PhD

Authors
  1. Mitsuhiro Yoshita MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuhiro Yoshita MD, PhD .

Editor information

Editors and Affiliations

  1. Dept. of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Rudi A.J.O. Dierckx

  2. Faculty of Electrical Engineering and Information Technology, University of Applied Sciences Offenburg, Offenburg, Germany

    Andreas Otte

  3. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Erik F.J. de Vries

  4. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Aren van Waarde

  5. Neurology, University Medical Center Groningen, Groningen, The Netherlands

    Klaus L. Leenders

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Yoshita, M. (2014). Value of MIBG in the Differential Diagnosis of Neurodegenerative Disorders. In: Dierckx, R., Otte, A., de Vries, E., van Waarde, A., Leenders, K. (eds) PET and SPECT in Neurology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54307-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54307-4_19

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54306-7

  • Online ISBN: 978-3-642-54307-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation